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RRM adjacent TARDBP mutations disrupt RNA
binding and enhance TDP-43 proteinopathy
Han-Jou Chen,1,2 Simon D. Topp,1 Ho Sang Hui,1 Elsa Zacco,1 Malvika Katarya,1
Conor McLoughlin,1 Andrew King,3 Bradley N. Smith,1 Claire Troakes,3 Annalisa Pastore1
and Christopher E. Shaw1,4
Amyotrophic lateral sclerosis (ALS) presents with focal muscle weakness due to motor neuron degeneration that becomes general-
ized, leading to death from respiratory failure within 3–5 years from symptom onset. Despite the heterogeneity of aetiology, TDP-
43 proteinopathy is a common pathological feature that is observed in 495% of ALS and tau-negative frontotemporal dementia
(FTD) cases. TDP-43 is a DNA/RNA-binding protein that in ALS and FTD translocates from being predominantly nuclear to form
detergent-resistant, hyperphosphorylated aggregates in the cytoplasm of affected neurons and glia. Mutations in TARDBP account
for 1–4% of all ALS cases and almost all arise in the low complexity C-terminal domain that does not affect RNA binding and
processing. Here we report an ALS/FTD kindred with a novel K181E TDP-43 mutation that is located in close proximity to the
RRM1 domain. To offer predictive gene testing to at-risk family members, we undertook a series of functional studies to char-
acterize the properties of the mutation. Spectroscopy studies of the K181E protein revealed no evidence of significant misfolding.
Although it is unable to bind to or splice RNA, it forms abundant aggregates in transfected cells. We extended our study to include
other ALS-linked mutations adjacent to the RRM domains that also disrupt RNA binding and greatly enhance TDP-43 aggrega-
tion, forming detergent-resistant and hyperphosphorylated inclusions. Lastly, we demonstrate that K181E binds to, and sequesters,
wild-type TDP-43 within nuclear and cytoplasmic inclusions. Thus, we demonstrate that TDP-43 mutations that disrupt RNA
binding greatly enhance aggregation and are likely to be pathogenic as they promote wild-type TDP-43 to mislocalize and
aggregate acting in a dominant-negative manner. This study highlights the importance of RNA binding to maintain TDP-43
solubility and the role of TDP-43 aggregation in disease pathogenesis.
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Introduction
Amyotrophic lateral sclerosis (ALS), also known as motor
neuron disease (MND), is the most common adult-onset
degenerative disease of motor neurons. The disease is char-
acterized by progressive motor neuron loss from the spinal
cord, brainstem and motor cortex, which subsequently
leads to muscle weakness and eventual respiratory failure.
The average age of disease onset is 55 years. Due to its
rapid progression, patients typically die within 3 to 5 years
of diagnosis. Riluzole remains the only licensed treatment
of ALS in the UK, but only marginally extends life expect-
ancy by a few months (Johnston et al., 2006; Wijesekera
and Leigh, 2009; Goyal and Mozaffar, 2014). The cause of
ALS is not yet completely deﬁned. The majority of ALS
patients have no apparent family history of the disease
and are categorized as sporadic, whereas 10% of cases
are familial. Regardless of the cause, 95% of patients
share a common molecular pathology featuring the accu-
mulation of ubiquitinated, hyperphosphorylated and deter-
gent resistant TDP-43 protein aggregates in the cytoplasm
of affected neuronal tissues (Neumann et al., 2006;
Mackenzie et al., 2007; Tan et al., 2007; Geser et al.,
2008; Pamphlett et al., 2009; Brettschneider et al., 2013).
In 2006, the accumulation of detergent-resistant, hyper-
phosphorylated TDP-43 was reported in affected neuronal
tissues of ALS and frontotemporal dementia (FTD) cases
(Neumann et al., 2006). Shortly afterwards, mutations in
TDP-43 were found in patients of both familial and spor-
adic ALS (Sreedharan et al., 2008). To date, there are more
than 50 mutations in TDP-43 reported to be associated
with ALS or FTD (for a review see Buratti, 2015) that
are estimated to account for 4% of familial ALS and
1.5% of sporadic ALS (Mackenzie et al., 2010). As
TDP-43 cytoplasmic aggregates are observed in 95% of
ALS and tau-negative FTD, the understanding of the mech-
anisms contributing to the build-up of TDP-43 proteinopa-
thy is critical in unravelling disease development and holds
the key to developing effective therapeutic strategies.
TDP-43 is a DNA and RNA binding protein predomin-
antly localizing in the nucleus but also shuttling between
the nucleus and cytoplasm. The architecture of TDP-43
comprises an N-terminal domain, two RRM RNA-binding
motifs and a C-terminal region often referred to as the
‘prion-like’ domain, which has low complexity and is en-
riched for glycine and serine residues. TDP-43 plays a key
role in regulating RNA transcription, editing, transport and
translation, and is involved in the formation of cellular
stress-induced stress granules in the cytoplasm (Belly
et al., 2005; Rutherford et al., 2008; Colombrita et al.,
2009; Dion et al., 2009; Nonaka et al., 2009). TDP-43 is
essential for organism development and survival (Kraemer
et al., 2010); however, an excessive amount of the protein
causes TDP-43 accumulation, which leads to cytotoxicity
and motor deﬁcits (Ash et al., 2010; Barmada et al., 2010;
Stallings et al., 2010; Wils et al., 2010). Therefore, it is not
surprising that the cellular levels of TDP-43 are under tight
control through a system of autoregulation (Ayala et al.,
2011; Polymenidou et al., 2011).
The majority of the TDP-43 disease-causing mutations
are in the C-terminal region of the protein. We and
others have shown that the C-terminal mutations promote
TDP-43 translocation to the cytosol, enhance protein sta-
bility and promote the aggregation of the mutant protein
which in turn leads to enhanced cytotoxicity in vitro and in
vivo (Johnson et al., 2009; Barmada et al., 2010; Ling
et al., 2010; Bilican et al., 2012; Mitchell et al., 2015).
As a DNA/RNA-binding protein, TDP-43 plays an import-
ant role in RNA regulation and transportation (Colombrita
et al., 2009; Lagier-Tourenne et al., 2010). However, the
role of RNA binding in the build-up of TDP-43 proteino-
pathy has never been investigated. In this study, we report
a novel FTD/ALS-linked mutation, K181E, which causes
catastrophic disruption in TDP-43 protein-RNA binding.
Investigating the impact of loss of RNA-binding on TDP-
43 proteinopathy further, we demonstrate that mutations
that leave TDP-43 incapable of binding RNA promote the
accumulation of insoluble aggregates in the nucleus and
cytoplasm, suggesting the loss of interaction with RNA
can be a factor contributing to the escalation of TDP-43
proteinopathy.
Materials and methods
Patient samples, exome capture and
variant analysis
DNA was available for both the index patient and his father.
Post-mortem brain and spinal cord tissue was available from
the index patient (donated to the London Neurodegenerative
Disease Brain bank with informed consent and under the
bank’s ethical approval: 08/MRE09/38 + 5). Both patients
had a diagnosis of deﬁnite ALS based on revised El Escorial
criteria (Ludolph et al., 2015), and full consent was given for
research purposes. DNA was isolated from whole blood and
the exome component captured using Roche NimbleGen
SeqCap EZ Exome V3 probes. Sequencing was performed on
an Illumina Hi-Seq 2000 and 100-bp paired-end reads
assembled to the hg19 human reference genome with
NovoCraft Novoalign. Variants were called with samtools
mpileup, normalized with bcftools norm and annotated using
Annovar and additional custom perl scripts. Variants were
quality ﬁltered at DP 5 10, GQ 5 50 and MQ 5 50.
Variants were excluded if they were present in 1000
Genomes or 670 local control exomes, more than once in
UK10K exomes, EVS exomes, or gnomAD genomes, or more
than three times in ExAC; frequencies that are comparable to
the most common conﬁrmed pathogenic ALS mutations in the
ALSoD database. Variants were further excluded if the locus
was covered at a depth 510 by 510 000 ExAC or
gnomAD-genome individuals, or if a focused inspection sug-
gested they were false positive variant calls. For this study,
gnomAD-exome is not a suitable resource for ﬁltering rare
variants as it contains exomes from several thousand patients
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with ALS. Assessment of pathogenicity was performed for all
non-synonymous variants by 20 different prediction tools
available from Annovar. Potential effects on splicing were as-
sessed for variants within 25 bp of a known splice site by
ADA, randomForest, Spidex, NetGene2 and GeneSplicer.
Homology modelling of the TDP-43 K181E mutation was
performed by Swiss-model, using PDB:4bs2 as a template, and
all images were rendered in PyMOL.
Immunohistochemistry
Sections of 7-mm thickness of human spinal cord tissue samples
in 10% formalin-ﬁxed, parafﬁn-embedded tissue blocks were
obtained from the London Neurodegenerative Diseases Brain
Bank. The parafﬁn-embedded tissue blocks were deparafﬁnized
in two changes of xylene and sequential percentage of ethanol
solutions for 3 min each (100%, 100%, 95%, 95%, 70%).
Antigen retrieval was performed by soaking the slides in 10
mM citrate buffer pH 6.0 and microwaved for 15 min. For
diagnosis, parafﬁn sections were stained for haematoxylin and
eosin and sections were immunohistochemically stained with
the rabbit polyclonal antibody to phosphorylated TDP-43
(pS409/410-2; 1:1500 Cosmo Bio); mouse monoclonal anti-
body to phosphorylated tau [clone (AT-8); 1:500; Autogen
Bioclear], -synuclein [clone (42/-synuclein); 1:500;
Novocastra Laboratories Ltd.], and amyloid-b (1:12 000;
Chemicon), using the Leica BONDMAXTM (Leica
Biosystems). Heat induced epitope retrieval was used for all
antibodies except for -synuclein and amyloid-b. For -synu-
clein, and amyloid-b, 80% formic acid pretreatment was used.
Nuclei were counterstained with Harris’ alum haematoxylin.
For immunoﬂuorescence staining, autoﬂuorescence was
blocked by the treatment of Sudan black (0.06 g in 20 ml of
70% ethanol) for 10 min. After blocking in normal serum, the
sections were stained and imaged as described in the
‘Immunoﬂuorescence’ section.
Plasmids and antibodies
The GFP-TDP-43 in pEGFP-C1 and HA-TDP-43 in pDEST30
plasmids were generated and used as in previous studies
(Nishimura et al., 2010; Scotter et al., 2015; Chen et al.,
2016). TDP-43 mutations were introduced using the Q5 Site-
Directed Mutagenesis Kit (NEB) with the following mutagen-
esis primers: K181E forward 50-CTTCCTAATTCTGAGC
AAAGCCAAG-30 and reverse 50-GAACCGAAACGAGTCT
TAATCCTTC-30; K181A forward 50-CTTCCTAATTCT
GCGCAAAGCCAAG-30 and reverse 50-TTTGCAGTCACAC
CATCG-30; D169G forward 50-CATATGATAGGTGGAC
GATGG-30 and reverse 50-TCGCTGTGACATTACTTTC-30;
K263E forward 50-CCGAACCTGAGCACAATAGC-30 and re-
verse 50-CATTGGATATATGAACGCTGATTCC-30. All plas-
mid sequences were veriﬁed by Sanger DNA sequencing.
Primary antibodies used for immunoblotting and immuno-
histochemistry in this study included: mouse anti-phospho
TDP-43 (1:3000, Cosmo Bio), rabbit anti-mouse TDP-43
(0.1 mg/ml, a gift from Prof. Virginia Lee) (Igaz et al., 2011),
mouse anti-Actin (1:4000, Sigma), mouse anti-GFP (1:1000,
Santa Cruz), rabbit anti-TDP-43 (1:2000, Proteintech),
mouse anti-GFAP (1:1000, Abcam) and mouse anti-HA
(1:1000, Cell Signaling). Primary antibodies used for immuno-
puriﬁcation included rabbit anti-GFP (1:2000, Abcam) and
rabbit anti-HA (C29F4) (1:500, Cell Signaling). Primary anti-
bodies used for immunoﬂuorescence included rabbit anti-ubi-
quitin, K48-speciﬁc (1:2000, Millipore), rabbit anti-p62
(1:10 000, Abcam), mouse anti-phospho TDP-43 (1:3000,
Cosmo Bio) and rabbit anti-TDP-43 (1:2000, Proteintech).
Secondary antibodies used included DyLightTM 680 goat
anti-rabbit IgG (1:10 000, Thermo Scientiﬁc), DyLightTM 800
goat anti-mouse IgG (1:10 000, Thermo Scientiﬁc), and
DyLightTM 488/550/650 anti-rabbit or mouse IgG (1:500,
Thermo Scientiﬁc).
Protein construct production and
purification for in vitro study
The wild-type tandem RRM domains of TDP-43 (RRM1-2,
K102-Q269) and the corresponding K181E mutant variant
were encoded in a pET-Sumo expression vector containing
the kanamycin antibiotic resistance gene. The plasmids were
expressed in a Rosetta2(DE3) Escherichia coli cell strain as
proteins fused with a SUMO solubilization tag carrying a
6His tag. Cells were grown in Luria-Bertani (LB) medium
containing 50 mg/ml kanamycin at 37C until an optical dens-
ity of 0.7 at 600 nm was reached. Protein expression was
induced at 18C by addition of 0.5 mM IPTG. Cells were
collected after overnight growth and resuspended in lysis
buffer (10 mM potassium phosphate buffer pH 7.2, 150
mM KCl, 5 mM imidazole, 5% v/v glycerol, 1 mg/ml lyso-
zyme, cOmpleteTM EDTA-free Protease Inhibitor tablet by
Roche, 1 mg/ml DNase I and 1 mg/ml RNaseA). Cells were
lysed by probe sonication and the soluble proteins recovered
by centrifugation at 70 000 rcf for 45 min at 4C. Protein
puriﬁcation included a ﬁrst nickel afﬁnity chromatography
step followed by overnight dialysis in the presence of the
Tobacco Etch Virus (TEV) protease at a 1:20 protein:TEV
molar ratio to remove the 6His-SUMO tag. A second
nickel-afﬁnity chromatography followed and the ﬂow-through
was loaded onto a HiTrap Heparin column to remove nucleic
acids. The protein constructs were ﬁnally submitted to size-
exclusion chromatography with a HiLoad 16/60 Superdex
75 prep grade in phosphate buffer pH 7.2. Protein purity
was checked by SDS-PAGE.
Spectroscopic measurements
Circular dichroism (CD) spectra were recorded on a JASCO-
1100 spectropolarimeter with a constant N2 ﬂush at 4.0 l/min.
CD datasets were an average of 15 scans. Far-UV spectrum
was recorded at 25C in phosphate buffer, pH 7.2. Spectra
were corrected for buffer signal and expressed as mean residue
molar ellipticity  (deg  cm2/dmol).
Uniformly and selectively 15N-labelled versions of wild-type
RRM1-2 and the K181E mutant were produced by standard
methods (Marley et al., 2001). 2D nuclear magnetic resonance
(NMR) 15N-HSQC (heteronuclear single quantum coherence)
spectra were recorded at 700 MHz frequency at 25C on
Varian spectrometers.
Aggregation kinetics assay
Protein aggregation was monitored by following the increment
in emission ﬂuorescence of the aggregate-speciﬁc dye
RRM mutations disrupting TDP-43 RNA binding BRAIN 2019: 0; 1–18 | 3
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ProteoStat on a FLUOstar Omega plate reader. Proteins were
diluted in phosphate buffer pH 7.2 to a concentration of 10
mM, with and without equal amount of the AUG-RNA (50-
GUGUGAAUGAAU-30). The plate was sealed with an optic
seal and the assay plates were incubated at 37C under, shak-
ing for 2 s (200 rpm) before each read (every 15 min). The
experiments were performed at least in triplicate and the re-
sults referred to the blank, normalized and reported as per-
centage average.
Cell culture and DNA transfection
HEK293T and SH-SY5Y cells were cultured using Dulbecco’s
modiﬁed Eagle medium (DMEM) and DMEM/F12
(Invitrogen) supplemented with 10% foetal bovine serum
(Invitrogen), and maintained at 37C, 5% CO2. Cells were
plated a day before transfection and media was refreshed
before plasmid DNA transfection using LipofectamineTM
2000 (Invitrogen). Cells were left for 48 h after transfection
to be harvested for analysis unless otherwise stated.
RNA extraction and RT-PCR
RNA was extracted using RNeasy Mini Kit (Qiagen). cDNA
was generated using 1 mg of RNA, oligo d(T) primer and
SuperScriptTM III First-Strand Synthesis Kit (Invitrogen). Fifty
nanograms of cDNA was used for RT-PCR with forward pri-
mers labelled with IRDye 700 at the 50 end. Primers used in
this study included: POLDIP3 forward 50-TGCTCTGAAG
CTCACCAAAA-30 and reverse 50-GGAACGGAAGCTATAC
CATCAT-30 (Tollervey et al., 2011); EGFP forward 50-CTG
AAGTTCATCTGCACCAC-30 and reverse 50-GGTCTTGTAG
TTGCCGTCG-30; GAPDH forward 50-CCTGACCTGCCGTC
TAGAAA-30 and reverse 50-ATCCTGGTGCTCAGTGTAGC
C-30. RT-PCR products were analysed by 2% agarose gel.
Images were taken by the Odyssey or GelDoc imaging
system and quantiﬁed by ImageJ (http://imagej.nih.gov/ij/).
Solubility fractionation
The fractionation for protein solubility was performed using a
protocol described by Winton et al. (2008) with some minor
modiﬁcations (Chen et al., 2016). Cells were harvested in
RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deox-
ycholate, 0.1% SDS, 50 mM Tris pH 8.0 and protease and
phosphatase inhibitors), sonicated and centrifuged at 12 000g
for 20 min at 4C. After centrifugation, the supernatant was
collected as the RIPA solubility fraction. The pellet, after being
washed once with RIPA buffer, was then suspended in 20% of
the original lysis volume with urea buffer (7 M Urea, 2 M
thiourea, 4% CHAPS and 30 mM Tris pH 8.5) and collected
as the insoluble, detergent-resistant fraction.
Immunopurification
Cells were harvested in IP buffer (50 mM Tris pH 7.4, 150
mM NaCl, 1% TritonTM X-100 with protease and phosphat-
ase inhibitor). After a short centrifuge (14 000 rpm for 30 s at
4C), the supernatant was collected and pre-cleaned with
Dynabead protein G (Invitrogen) 2 h at 4C. The pre-cleaned
lysate was then incubated with immunopuriﬁcation antibody
and fresh Dynabead protein G (Invitrogen) overnight at 4C.
The Dynabead protein G-antibody-protein complex was pur-
iﬁed using magnetic separation and washed with IP buffer
before elution in loading buffer.
Western blotting and densitometry
analysis
Protein quantiﬁcation and western blotting were performed as
described before (Nishimura et al., 2010; Chen et al., 2016).
Five micrograms of cell lysate from the RIPA fraction and the
equivalent liquid volume from the urea fraction were loaded.
Western blot quantiﬁcation were performed used the image
analysis software, ImageJ (http://imagej.nih.gov/ij/). Integrated
band intensities were normalized to that of loading control or
the RIPA fraction.
Immunofluorescence
Cells for immunoﬂuorescent analyses were ﬁxed in 4%
paraformaldehyde (VWR) for 20 min and washed with phos-
phate-buffered saline (PBS) three times for 5 min. Cells were
permeabilized by incubation in PBS containing 0.5% TritonTM
X-100 (Sigma) for 15 min at room temperature, followed by
blocking in PBS containing 1% donkey serum for 1 h at room
temperature. Cells were incubated with primary antibody
diluted in blocking solution overnight at 4C. After washing
in PBS, cells were subsequently incubated with ﬂuorescent sec-
ondary antibodies diluted in blocking solution for 1 h at room
temperature. DAPI (Sigma) was then used to stain for nuclei
before being mounted on coverslips using FluroSave
(Calbiochem).
RNA electrophoretic mobility-shift
assay
Using the LightShift Chemiluminescent RNA EMSA Kit
(electrophoretic mobility-shift assay, EMSA) (Thermo
Fisher), 5 mg of total cell lysate in RIPA containing RNase
inhibitor (NEB) was mixed with 2 mg of tRNA, 1 mM of
unlabelled (GU)6 RNA and 2.5 nM of biotin-labelled
(GU)6 RNA (CGUGUGUGUGUGUGGU) (Bhardwaj et
al., 2013) and was incubated for 30 min at room tempera-
ture. The binding reactions were run on a 6% non-denatur-
ing polyacrylamide gel, followed by semi-dry transfer (3 mA/
cm2, 30 min) to Hybond-N + nylon membrane (GE
Healthcare) and UV cross linking (120 mJ/cm2). Biotin-
labelled RNA was detected by chemiluminescence with sta-
bilized streptavidin-horseradish peroxidase conjugate pro-
vided by the RNA EMSA kit.
Fluorescence recovery after
photobleaching
HEK293T cells (106) per well were plated on the 15m-Slide 8
well chamber slide (Ibidi) the day before transfection. Cells
were transfected with GFP-TDP-43 for 48 h and Hoechst
staining (1 mg/ml, Thermo Fisher) was applied 20 min
before imaging.
Fluorescence recovery after photobleaching (FRAP) was
performed using a Nikon A1R laser scanning confocal
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microscope ﬁtted with an environmental chamber main-
tained at 37C. Confocal images of 512  512 pixels were
acquired using a 60 oil immersion objective. Five frames
were acquired before bleaching (10% laser power, 4 frames/s
of 10 loops) a 3  3 mm2 region of interest. Fluorescence
recovery was followed for 1 min after bleaching. Data ana-
lysis was performed using Nikon Elements software as
per manufacturer’s instruction. The EGFP ﬂuorescence inten-
sity at each time point was measured for the bleached re-
gion of interest as well as for an unbleached reference
region of interest of the same size to correct for acquisition
bleaching. FRAP recovery for the bleached region of interest
was calculated by ﬁrst subtracting the reference at each time
point and then normalized to the pre-bleached ﬂuorescence
intensity.
Data availability
The data supporting the ﬁndings of this study are available
from the corresponding author on request.
Results
Identification of novel RRM-adjacent
TARDBP mutation in a familial ALS/
FTD kindred
A 38-year-old male patient presented with predominantly
lower motor neuron signs that progressed over 48
months to a ﬂaccid tetraparesis, but he was still able to
speak and had normal cognitive function. His father de-
veloped lower motor neuron signs in his upper limbs at
the age of 76 and 6 months later developed major per-
sonality and behavioural changes consistent with a clin-
ical diagnosis of FTD that eventually led to profound
cognitive deﬁcits. Brain MRI was consistent with a diag-
nosis of FTD. The index patient survived 80 months
from symptom onset and his father survived 36 months
(Fig. 1A). The brain and spinal cord tissues from the
index patient were available for further neuropatho-
logical examination
The formalin ﬁxed left half of the brain weighed 782 g.
There was some slight cerebral swelling noted but no cere-
bral atrophy. No other macroscopical abnormality was
seen in the brain. The spinal cord did show some evidence
of thinning of anterior nerve roots. Histologically the
spinal cord showed loss of anterior horn neurons and
some surviving neurons contained Bunina bodies
[Fig. 1B(i)]. Immunohistochemistry revealed phosphory-
lated (p)TDP-43-positive skein-like inclusions in the neu-
rons [Fig. 1B(ii)], and numerous pTDP-43-positive
cytoplasmic inclusions in glial cells [Fig. 1B(iii)] . There
was loss of myelin in the lateral and anterior corticospinal
tracts of the cord, indicating upper motor neuron loss.
Indeed within the motor cortex there was loss of Betz
cells, and many surviving Betz cells contained pTDP-43-
positive neuronal [Fig. 1B(iv)] cytoplasmic inclusions.
There were pTDP-43-positive neuronal [Fig. 1B(v)] and
glial cytoplasmic inclusions in the XIIth nerve nucleus of
the medulla, and also the midbrain, basal ganglia and
amygdala but not the hippocampus or neocortex. The
glial cells containing cytoplasmic TDP-43 inclusions were
GFAP-positive (Fig. 1C) but MBP-or CD68-negative (data
not shown), showing that cytoplasmic TDP-43 accumula-
tion was present in astrocytes but not seen in oligodendro-
cytes or microglia. There was no tau, amyloid-b or -
synuclein pathology present.
NimbleGen exome capture and Illumina sequencing
were carried out on whole blood DNA for both the
father and son, resulting in 134 million and 160 million
100-nucleotide paired-end reads, respectively, which
when assembled to the human reference genome, covered
91.76% of the coding bases in Refseq to a depth 510
in both samples. A relaxed ﬁltering strategy identiﬁed 29
candidate variants present in both affected family mem-
bers (Supplementary Table 1), 11 of which were not pre-
sent in the 1000 Gnomes, UK10K, EVS/ESP, ExAC, or
gnomAD variant databases, nor in 670 local controls.
One of these variants was of paramount interest as it
represented a novel missense change in the RNA-binding
domain of TDP-43 (TARDBP: NM_007375:c.541
A4G:p.Lys181Glu) (K181E), predicted to be damaging
by 15 of 20 prediction tools used to assess pathogenicity.
The heterozygous mutation of TDP-43 K181E was
validated with Sanger DNA sequencing (Fig. 1D) and is
predicted to substitute a positively-charged lysine (K) resi-
due adjacent to the ﬁrst RNA-binding domain with a
negatively-charged glutamic acid (E). The K181E
mutation lies adjacent to the RRM1 whereas most ALS-
associated mutations cluster at the ‘prion-like’ domain
(Fig. 1E)
The structure of the tandem RRM
domains is not altered by the K181E
mutation
We speculated on a possible destabilizing effect of the
K181E mutation on the structure of TDP-43. Because of
the known difﬁculties in working with full-length TDP-43
in vitro (Johnson et al., 2009), we produced a construct
containing the two tandem RRM domains of TDP-43,
here called RRM1-2, as heterologous protein expressed in
E. coli, both as wild-type and as a K181E mutant to inves-
tigate the mutation effect.
CD spectroscopy was used to compare the overall sec-
ondary structure of the two variants (Fig. 2A). Both spectra
displayed the signature typical of folded -b proteins and
overlapped both in shape and signal intensity, indicating
that the secondary structure is not altered by the K181E
mutation. We also investigated the potential local effect of
the mutation by NMR HSQC spectroscopy (Fig. 2B). The
RRM mutations disrupting TDP-43 RNA binding BRAIN 2019: 0; 1–18 | 5
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2D spectra resulted highly similar, both in terms of chem-
ical shifts and relative resonance intensities, indicating that
mutation of K181 to E does not affect the chemical envir-
onment of the protein.
These results clearly exclude that the K181E mutation
could alter the structure of the tandem RRM motifs and
led us to believe that the effect on the native conformation
of full-length TDP-43 is not structural.
Figure 1 Identification of the K181E mutation in a family of ALS/FTD. (A) The pedigree of the ALS/FTD kindred carrying the K181E
mutation is shown. Affected individuals are indicated by shaded symbols, deceased individuals with a slash, and numbers indicate current age or
age at death. (B) Brain and spinal cord pathology of index patient. [B(i)] Bunina bodies (arrow) observed in a slightly atrophic anterior horn
neuron from the spinal cord. [B(ii)] Granular/skein-like pTDP-43-positive cytoplasmic inclusion in an atrophic anterior horn neuron from the
spinal cord. [B(iii)] A pTDP-43-positive glial cytoplasmic inclusion within the spinal cord. [B(iv)] A motor neuron from the motor cortex
containing granular cytoplasmic pTDP-43-positive inclusions. [B(v)] The XIIth nerve nucleus of the medulla showing skein-like (arrowhead) and
granular (black arrow) cytoplasmic pTDP-43-positive neuronal inclusions. Scale bar = 50 mm in i, ii, iv, v; 20 mm in iii. (C) Cytoplasmic TDP-43
[C(i), arrow] and p-TDP-43-positive inclusions [C(ii), arrows] observed in GFAP-positive cells. Images were taken in the area of anterior horn
from the spinal cord. Scale bar = 5 mm. (D) Sanger sequencing chromatogram demonstrating a wild-type control and a heterozygous single base
substitution (c.541A4G) predicted to substitute lysine for glutamic acid (p.Lys181Glu, K181E) in the index patient and his father. (E) Schematic
overview of TDP-43 protein domain structure and disease-associated mutations.
6 | BRAIN 2019: 0; 1–18 H.-J. Chen et al.
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/b
ra
in
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/b
ra
in
/a
w
z
3
1
3
/5
5
8
5
9
4
0
 b
y
 g
u
e
s
t o
n
 1
4
 O
c
to
b
e
r 2
0
1
9
K181E decreases TDP-43 protein
solubility and enhances
hyperphosphorylation
In ALS and FTD, pathological TDP-43 protein accumulates
in affected neurons, forming hyperphosphorylated and de-
tergent-resistant aggregates. In an earlier study, we
observed elevated levels of insoluble and hyperphosphory-
lated TDP-43 following the overexpression of both wild-
type and ALS-associated C-terminal TDP-43 mutants (Chen
et al., 2016). To investigate whether the novel RRM-
domain K181E mutation is pathological and causes TDP-
43 aggregation, we used the same cellular model transiently
overexpressing EGFP-tagged full length TDP-43 in
HEK293T cells. Levels of C-terminal mutant M337V and
Q331K protein in the urea-soluble fraction was similar to
wild-type protein but levels of insolubility and phosphoryl-
ation of the K181E mutant protein were increased 2- to 4-
fold, respectively (Fig. 3). Similar results were also found
when the same EGFP-TDP-43 constructs were expressed in
the neuroblastoma cell line, SH-SY5Y (Supplementary Fig.
1), validating the profound effect of the K181E mutation in
enhancing features of TDP-43 proteinopathy. Although the
K181E mutation lies well outside the C-terminal domain
and does not have a signiﬁcant impact on the structure of
the RRM1-2 area (Fig. 2), the increased levels of hyperpho-
sphorylated and insoluble TDP-43 protein are consistent
with it being pathological.
K181E disrupts TDP-43 binding to
target RNA and promotes nuclear
aggregation
The majority of ALS-associated TDP-43 mutations have so
far been found to occur within the low complexity ‘prion-
like’ C-terminal domain (amino acids 274 to 414, Fig. 1E),
which is involved in interactions with other proteins
(Buratti et al., 2005; D’Ambrogio et al., 2009; March et
al., 2016). Although the mechanism(s) of C-terminal
mutant protein toxicity are not clear, they have a longer
half-life than wild-type TDP-43 and are more prone to
form cytoplasmic aggregates (Barmada et al., 2010; Ling
et al., 2010). The K181E mutation, however, is adjacent
to the RRM1 domain, which plays a dominant role in
DNA and RNA binding (Buratti and Baralle, 2001; Kuo
et al., 2009; Che et al., 2015). The crystal structure of a
peptide containing both TDP-43 RRM domains bound to a
GU-rich-RNA strand has been resolved (PDB:4bs2) and
shows that the lysine residue at 181 lies within one wall
of a pocket-like cavity into which a guanine nucleotide is
bound (Fig. 4A, B and Supplementary Video 1; Lukavsky
et al., 2013). As the lysine residue is positively charged, it
will have a greater afﬁnity for negatively-charged DNA or
RNA nucleotides than the negatively-charged mutant glu-
tamic acid (E), which is predicted to create an electrostatic
repulsion between the protein and the nucleotide (Fig. 4B)
that could reduce the RNA-binding capacity of TDP-43.
We therefore investigated the interaction between the
TDP-43 protein and a known RNA target, (GU)6
(Bhardwaj et al., 2013) using an electromobility shift
assay (EMSA). Wild-type GFP-TDP-43 showed highly efﬁ-
cient binding to (GU)6 RNA, as did Q331K and M337V
TDP-43 (Fig. 4C); however, this interaction was completely
abolished by the K181E mutation (Fig. 4C). This loss of
RNA-binding of K181E TDP-43 was also shown by its
inability to regulate the splicing of its target RNAs, such
as POLDIP3 (Fig. 4D and E). Wild-type, Q331K and
M337V all enhanced the exclusion of POLDIP3 exon 3
but K181E failed to splice out this exon (Fig. 4D and E).
Interestingly, in addition to the occasional cytosolic hyper-
phosphorylated aggregates seen in wild-type TDP-43
Figure 2 Structural comparison of the wild-type and K181E tandem RRM domains. (A) CD spectra acquired at room temperature,
indicating almost complete overlap in their secondary structure. (B) Superposition of heteronuclear single quantum coherence (HSQC) ex-
periments showing that the two variants have nearly identical NMR spectra. Black = wild-type RRM1-2; red = K181E RRM1-2.
RRM mutations disrupting TDP-43 RNA binding BRAIN 2019: 0; 1–18 | 7
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overexpression, K181E TDP-43 frequently formed nuclear
aggregates that were also hyperphosphorylated (Fig. 4F),
which implies that RNA binding in the nucleus may pre-
vent aberrant TDP-43 aggregation.
The impact of K181E mutation on RNA interaction
observed in RNA-EMSA was validated in an in vitro
study where we used the RRM1-2 wild-type and K181E
mutant constructs and determined the dissociation constant
(Kd) of the interaction with AUG RNA by means of bio-
layer interferometry. We found that wild-type RRM1-2
binds the UG-rich AUG RNA with a Kd of 3.2  0.9
nM, while the K181E mutant displayed a Kd of 2.5 
0.4 mM (Supplementary Fig. 2).
We can thus conclude that, while not having any struc-
tural relevance, the mutation leads to severe impairment of
function and prevents the interaction between TDP-43 pro-
tein and its target RNA, which is crucial for effective spli-
cing and trafﬁcking. Our data have also shown that the
K181E-TDP-43 is unable to bind and process RNA and
is highly prone to aggregation.
Disruption of RNA binding enhances
TDP-43 phosphorylation and
aggregation
To dissect the relationship between RNA binding and TDP-
43 proteinopathy further, we extended our study to other
missense variants that occur in or around the RRM do-
mains, including K181A, D169G and K263E. The K181A
variant is an artiﬁcial construct generated to test the afﬁnity
of RNA for the RRM1 of TDP-43, which was shown to be
unaffected (Fig. 5A; Lukavsky et al., 2013). The D169G
mutation was identiﬁed in one sporadic ALS case
(Kabashi et al., 2008) and shown not to have any impact
on RNA binding in in vitro studies despite its location at
Figure 3 The K181E mutation increases TDP-43 detergent-resistance and phosphorylation. (A) HEK293T cells expressing GFP-
TDP-43 constructs for 48 h, followed by fractionation. Phospho-TDP-43 specific antibody is used to visualize phospho-TDP-43 and TDP-43
antibody for total overexpressed GFP-TDP-43. Levels of GFP-TDP-43 (B and C) and phospho-TDP-43 (D) from three independent transfections
were quantified, normalized to actin and shown in relation to GFP-WT TDP-43. Mean and standard error of the mean (SEM) are shown for the
soluble (B), and insoluble (C and D) fractions. The data were analysed by one-way ANOVA followed by Bonferroni post-test. Significant increases
in detergent-resistance and protein phosphorylation is found with K181E-TDP-43 (P 5 0.01 for both). WT = wild-type.
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Figure 4 The K181E mutation disrupts the interaction between TDP-43 protein and RNA interaction, which prevents splicing
of target RNA and increases TDP-43 aggregating. (A) Crystal structure of TDP-43 N-terminal fragment (pdb:4bs2) containing two RRM
domains (red helices, yellow beta sheets) interacting with a GU-rich RNA strand (blue/orange spheres), showing TDP-43 lysine 181 (purple
spheres) to be in close contact with a guanine nucleotide. (B) Close-up of the guanine-binding pocket formed by D105, F149, K181, R197 and
S254 (i) is not altered structurally altered by the E181 mutation (ii); however, the positively-charged cavity (iii) gains a strongly negative
electrostatic charge in the presence of the ALS-linked mutation (iv). (C) RNA-EMSA using total cell lysate from 48 h GFP-TDP-43 transfected
HEK293T cells and biotin-labelled (GU)6 RNA. Western blots (WB) of GFP-TDP-43 actin are used to demonstrate uniform expression of GFP-
TDP-43 and protein loading; n = 3. (D) Endogenous POLDIP3 mRNA splicing assay using RNA extracted from 48 h GFP-TDP-43 transfected
HEK293T cells. RT-PCR for POLDIP3, EGFP and GAPDH was carried out to show the TDP-43-mediated mRNA splicing activity, transfection
efficiency and loading. (E) The levels of POLDIP3 long and short transcripts from three independent studies were quantified. Means and SEMs are
shown. The data were analysed by one-way ANOVA followed by Bonferroni post-test. Wild-type, Q331K- and M337V-TDP-43 significantly alter
the splicing profile of POLDIP3 (P5 0.05) whereas K181E-TDP-43 does not have any significant impact, compared to untransfected or GFP-only
control. (F) Phospho-TDP-43 staining (red) in HEK293T cells transfected for 48 h with GFP wild-type or K181E-TDP-43. Scale bar = 10 mm.
RRM mutations disrupting TDP-43 RNA binding BRAIN 2019: 0; 1–18 | 9
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Figure 5 Disruption of RNA binding enhances TDP-43 protein aggregation and phosphorylation. (A) RNA EMSA using total cell
lysate from 48 h GFP-TDP-43 transfected HEK293T cells and biotin-labelled (GU)6 RNA. Western blots of GFP-TDP-43 and actin demonstrate
the equal expression of GFP-TDP-43 constructs and protein loading. (B and C) HEK293T cells express GFP-TDP-43 constructs for 48 h followed
by fractionation. GFP or phospho-TDP-43-specific antibody was used to visualize total GFP-TDP-43 (B) or phospho-TDP-43 (C). (D and E)
Phospho-TDP-43 staining (red) in HEK293T cells transfected for 48 h with GFP-TDP-43. Scale bar = 10 mm. Cell counting was carried out
manually under fluorescence microscope. At least 200 GFP-positive cells were counted for each condition, per transfection, using an unbiased
protocol as described previously (Lee et al., 2013). One-way ANOVA and Bonferroni post-test shows that there are significantly more nuclear
TDP-43-containing cells in both K181E- and K263E-TDP-43-expressing conditions (P 5 0.0001). (F and G) FRAP was carried out after 48 h of
GFP-TDP-43 transfection in HEK293T cells. A 3  3 mm2 area (indicated with white box) was bleached with fluorescence and recovery recorded
for 1 min after bleaching. Hoechst 33342 staining (blue) was used to visualize the nucleus. Scale bar = 10 mm. Five cells were bleached and
recorded for each condition, per transfection. Means and SEMs of three transfections are plotted in G. (H and I) Fluorescence-associate
aggregation kinetics in the absence and presence of RNA. The percentage of aggregation reduction of the wild-type-RRM1-2 (H) or K181E-RRM1-
2 (I) protein constructs due to the presence of RNA is indicated by an arrow at a 1:1 protein:RNA molar ratio. All experiments were repeated at
least three times.
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the RRM1 domain (Fig. 5A; Austin et al., 2014; Kuo et al.,
2014), nor functional disruption to full length TDP-43
(McDonald et al., 2011; Vanden Broeck et al., 2015). We
were able to conﬁrm that neither K181A nor D169G vari-
ants disrupt RNA binding (Fig. 5A). Alanine has a neutral
charge and is therefore less likely to repel nucleotides at
position 181, while the substitution of aspartic acid (D)
to glycine (G) at positon 169 is distant from the RNA-
binding interface and unlikely to cause direct steric or elec-
trostatic disruption (Supplementary Fig. 3). K263E was
identiﬁed in one patient diagnosed with sporadic FTD
(Kovacs et al., 2009) and in cellular studies this mutation
was shown to increase TDP-43 stability and enhance its
ubiquitination (Austin et al., 2014; Hans et al., 2014).
Here we show that, like K181E, the K263E mutation
also disrupts the capacity of TDP-43 to bind RNA
(Fig. 5A). Interestingly, K263 in the RRM2 domain
shares structural and functional homology with the K181
residue in the RRM1 domain, in that it contributes to
forming a positively-charged groove into which a guanine
nucleotide is shown to ﬁt. The negatively-charged glutamic
acid (E) residue in this position in the RRM2 domain is
also predicted to repel negatively-charged nucleotides and
inhibit RNA binding.
The K181E and K263E mutants also had much higher
levels of phosphorylation and reduced solubility compared
to wild-type- and the D169G-TDP-43 mutation on western
blots (Fig. 5B and C) and were more likely to form phos-
phorylated intra-nuclear aggregates (30% of transfected
cells, Fig. 5D and E) compared to wild-type-, D169G-
and K181A-TDP-43, which have a diffuse distribution in
the nucleus (Fig. 5D and E). Although K181A did not dis-
rupt RNA binding in our in vitro assay (Fig. 5A), it did
show a modest increase in detergent-resistant phosphory-
lated intra-nuclear aggregates (Fig. 5C and D). FRAP ana-
lysis of the nuclear TDP-43 aggregates demonstrated that
they were highly immobile compared to diffuse nuclear
wild-type, D169G or M337V TDP-43, or the nuclear lo-
calization signal (NLS) deleted cytoplasmic (dNLS) TDP-43
(Fig. 5F, G and Supplementary Videos 2 and 3).
Recently, we showed that UG-rich RNA can signiﬁcantly
reduce the aggregation of TDP-43 RNA-recognition regions
(Zacco et al., 2019). We used the aggregation detection
ﬂuorophore ProteoStat, which allows us to monitor aggre-
gate formation as a function of time. We normalized the
data as referred to the value reached at end of the assay (3
days). In the absence of UG-rich RNA, wild-type RRM1-2
exhibited time-dependent self-assembly (Fig. 5H). When
RNA was added in a 1:1 ratio, the percentage of aggregates
recorded for the wild-type after 3 days was only 34% the
value detected in the absence of RNA, indicating a RNA-
dependent aggregation inhibition of RRM1-2 aggregation
of 66% (Fig. 5H). When the same level of RNA was added
to the K181E mutant aggregate formation was reduced
only by 5% (Fig. 5I), suggesting that the weak interaction
with this RNA translate into a weak inhibitory effect on the
aggregation behaviour.
The amino acids surrounding K181 are the most con-
served region in TDP-43, in particular the 109 amino
acids from the C-terminal half of RRM1 (Phe152) to the
end of RRM2 (Ala260), which are completely devoid of
any nonsense or missense variants in the ExAC database
(Supplementary Fig. 4). This high level of conservation in-
dicates that this region plays a crucial role in TDP-43 func-
tionality and that there has been a strong selection pressure
against changes to the RRM domains. Speciﬁc mutations
such as K181E and K263E in this highly conserved region
disrupt RNA binding and promote the accumulation of
detergent resistant, hyperphosphorylated, immobile nuclear
TDP-43 aggregates conferring likely pathogenicity. It is also
interesting to note that the capacity to interact with RNA
may play an important role in maintaining TDP-43 solu-
bility and functionality.
K181E-TDP-43 interacts and recruits
wild-type endogenous TDP-43
protein to nuclear aggregates
TDP-43 is an aggregation-prone protein that forms oligo-
mers under physiological conditions and detergent-resistant
aggregates in disease and overexpression cellular and trans-
genic models (Neumann et al., 2006; Mitchell et al., 2015;
Chen et al., 2016; Afroz et al., 2017). To investigate the
interaction between mutant and wild-type proteins, we
co-expressed wild-type and K181E HA- and GFP-tagged
constructs (Fig. 6A). Overexpression of haemagglutinin
(HA)- and GFP-tagged wild-type-TDP-43 generated occa-
sional hyperphosphorylated TDP-43 cytoplasmic aggregates
that consisted of both HA- and GFP-wild-type TDP-43 pro-
teins. Co-aggregation was far more abundant in wild-type-
and K181E-TDP-43 co-expressing cells predominantly
within the nucleus (Fig. 6A and B). The interaction between
wild-type- and mutant-TDP-43 proteins was conﬁrmed as
co-immunoprecipitation of HA-tagged wild-type and
mutant TDP-43 consistently pulled down the GFP-tagged
wild-type TDP-43 protein, which was most abundant with
HA-K181E and K263E bait (Fig. 6C). Thus aggregation of
mutant or wild-type protein in the cytoplasm or nucleus is
able to recruit endogenous wild-type protein (Fig. 6D) and
could thereby interfere with RNA processing.
In summary, we have shown that although K181E and
K263E ALS and FTD-associated mutants of TDP-43 do not
directly bind RNA, they are able to disrupt RNA process-
ing by sequestering endogenous wild-type TDP-43 protein
within hyperphosphorylated aggregates, which could have
signiﬁcant functional consequences.
Disruption of cytoplasmic TDP-43
RNA binding aggravates TDP-43
proteinopathy
TDP-43 is predominantly a nuclear protein; however, it is
known to shuttle between the nucleus and cytoplasm,
RRM mutations disrupting TDP-43 RNA binding BRAIN 2019: 0; 1–18 | 11
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Figure 6 K181E mutant TDP-43 binds to wild-type-TDP-43 and sequesters it in phosphorylated intranuclear and cytoplasmic
inclusions. (A and B) HEK293T cells co-expressing GFP WT- or K181E-TDP-43 and HAWT-TDP-43 for 48 h were fixed and stained with HA
(red) and phospho-TDP-43 (magenta). Cytoplasmic hyperphosphorylated TDP-43 aggregates (arrowhead) were seen in both conditions; nuclear
hyperphosphorylated aggregates containing both wild-type (WT) and K181E-TDP are indicated by arrows. (C) Co-immunopurification of GFP-
WT or mutant TDP-43 and HA wild-type-TDP-43. HA WT-TDP-43 was pulled down by the HA antibody and GFP-TDP-43 detected with the
TDP-43 antibody. (D) Interaction between GFP-K181E TDP-43 and endogenous wild-type TDP-43 in the mouse neuronal cell line, N2a. After
48 h transfection with GFP-TDP-43, cells were fixed and stained by phospho-TDP-43-specific antibody (red) and the mouse TDP-43-specific
antibody (magenta). Scale bar = 10 mm. All experiments were repeated at least three times.
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playing a crucial role in regulating RNA transport, metab-
olism and local cytoplasmic translation (Liu-Yesucevitz
et al., 2011; Fallini et al., 2012; Yasuda and Mili, 2016).
To investigate the inﬂuence of RNA binding on the behav-
iour of cytoplasmic TDP-43, we introduced the K181E mu-
tation into a TDP-43 construct lacking the nuclear
localizing signal (GFP-dNLS TDP-43), which is preferen-
tially retained in the cytoplasm. Interestingly, the K181E
mutation substantially increased levels of hyperphosphory-
lated TDP-43 detergent resistant aggregates (Fig. 7A–C and
Supplementary Fig. 5A), which were localized to the cyto-
plasm in both HEK293T and SH-SY5Y cells (Fig. 7B, C
and Supplementary Fig. 5B). Protein aggregates associated
with neurodegenerative disorders are often decorated with
proteins that facilitate protein degradation such as ubiqui-
tin and p62 (Arai et al., 2003; Neumann et al., 2006).
Although nuclear and cytoplasmic aggregates of wild-type
and mutant TDP-43 were labelled with ubiquitin, p62
stains more intensively with cytoplasmic aggregates and
weaker with nuclear aggregates associated with the
K181E mutation (Fig. 7D and E).
The formation of hyperphosphorylated TDP-43 cytoplas-
mic and, less commonly, nuclear aggregates, are a hallmark
feature of ALS and FTD, but the factors that contribute to
their development are not fully understood. We have con-
ﬁrmed that some disease-associated mutations adjacent to
RRM1 and RRM2 disrupt RNA binding and form nuclear
and cytoplasmic aggregates. This may impair RNA process-
ing through the sequestration of wild-type protein, acting in
a dominant-negative fashion. Furthermore, the binding to
its target RNA plays an important role in maintaining the
solubility of TDP-43 protein. Disruption of RNA binding
promotes TDP-43 to aggregate in the cytoplasm as well as
in the nucleus.
Discussion
Mutations in TARDBP linked to ALS and FTD and are
associated with phosphorylated cytoplasmic TDP-43 aggre-
gates in degenerating neurons (Sreedharan et al., 2008;
Kovacs et al., 2009; Synofzik et al., 2014). Using exome
sequencing, we detected a novel K181E TARDBP mutation
in a father and son with classical ALS/FTD and ALS, re-
spectively, and we excluded mutations in all other known
ALS and FTD genes. More than 90% of all TDP-43 mu-
tations are located in the low-complexity C terminal
domain and the pathogenicity of this variant, which is situ-
ated adjacent to the dominant DNA/RNA-binding domain
RRM1, was unknown. Our 3D modelling showed that
K181E and K263E, but not D169G, were predicted to
reduce the positive charge within the nucleotide binding
site. Here we have conﬁrmed that K181E and K263E,
but not D169G, disrupted RNA binding to these mutant
proteins and abolished splicing of its endogenous RNA
target POLDIP3. The loss of RNA binding by these two
mutants was associated with a dramatic increase in TDP-43
protein phosphorylation, insolubility and aggregation, pre-
dominantly within the nucleus and to a lesser extent in the
cytoplasm. We have demonstrated that wild-type TDP-43 is
recruited to mutant aggregates that may exert a dominant-
negative effect on RNA processing in the nucleus and
cytoplasm.
TDP-43-mediated RNA regulation in
health and disease
As a DNA/RNA-binding protein, TDP-43 is known to
physically bind to mRNAs and miRNAs to regulate their
splicing, stability, transport and translation (Ayala et al.,
2005; Buratti et al., 2010; Polymenidou et al., 2011;
Tollervey et al., 2011; Humphrey et al., 2017). In addition
to its role in normal RNA processing, TDP-43 has recently
been shown to serve as a chaperone for toxic RNA, such as
the UGGAA repeat expansion associated with spinocerebel-
lar ataxia type 31 (SCA31) (Niimi et al., 2013; Ishiguro et
al., 2017). Functional disruption of TDP-43 RRM domains
abolishes this interaction and results in the accumulation of
(UGGAA)n RNA foci and repeat-associated pentapeptide,
which leads to neurodegeneration (Ishiguro et al., 2017).
On the other hand, because of its role in RNA regulation,
changes in TDP-43 protein levels impact on a vast number
of its target RNAs, leading to alterations in the levels and
splicing patterns of the cellular RNA proﬁle (Polymenidou
et al., 2011; Zhang et al., 2012). Knockdown of TDP-43 in
cells or animals impacts widely on the levels and splicing
pattern of a vast number of RNA transcripts (Polymenidou
et al., 2011; Ling et al., 2015). Whereas the investigations
into altered RNA proﬁles of ALS patients verify some of
the changes observed in the knockdown study, the variance
between human studies are simply too big to draw a con-
sistent conclusion (Polymenidou et al., 2011; Shiga et al.,
2012; Brohawn et al., 2016; D’Erchia et al., 2017).
A loss-of-function hypothesis has long been speculated as
a mechanism underlying TDP-43-associated disease patho-
genesis. Systematic knockout of TDP-43 in mice results in
embryonic lethality (Kraemer et al., 2010; Sephton et al.,
2010; Wu et al., 2010) indicating that TDP-43 plays a
crucial irreplaceable role during early embryo development.
On the other hand, targeted depletion of TDP-43 in adult
mouse motor neurons induces ALS-like progressive motor
dysfunction and muscle atrophy (Wu et al., 2012; Iguchi et
al., 2013), with similar results reported in Drosophila
(Feiguin et al., 2009; Fiesel et al., 2010; Lin et al., 2011;
Diaper et al., 2013) and Caenorhabditis elegans (Vaccaro
et al., 2012; Zhang et al., 2012). Collectively, these studies
indicate that TDP-43 plays an import role in maintaining
the function and wellbeing of motor neurons. Interestingly,
knockdown of endogenous TDP-43 shows the same impact
on POLDIP3 splicing as overexpression of wild-type TDP-
43 alone (Figs 4C and 5D) (Fiesel et al., 2010; Shiga et al.,
2012; Suzuki et al., 2015), which indicates that TDP-43
needs to be maintained at a critical level, lower and
RRM mutations disrupting TDP-43 RNA binding BRAIN 2019: 0; 1–18 | 13
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Figure 7 Disruption of cytoplasmic TDP-43 RNA binding aggravates TDP-43 proteinopathy. (A) HEK293T cells expressing GFP-
TDP-43 constructs for 48 h followed by fractionation. GFP and phospho-TDP-43-specific antibodies were used to visualize total GFP-TDP-43 and
phospho-TDP-43. Endogenous TDP-43 proteins are shown by TDP-43 antibody, and actin is shown as a loading control. (B–E) HEK293T cells
expressing GFP-TDP-43 for 48 h were fixed and stained with phospho-TDP-43 (red), p62 (magenta; D) and ubiquitin (magenta; E). DAPI (blue) is
used to visualize the nucleus. Scale bar = 10 mm. The percentage of GFP-dNLS and GFP-dNLS K181E TDP-43 aggregation were quantified via cell
counting as described before (Lee et al., 2013). Means and SEMs are shown in C. All experiments were repeated at least three times.
14 | BRAIN 2019: 0; 1–18 H.-J. Chen et al.
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/b
ra
in
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/b
ra
in
/a
w
z
3
1
3
/5
5
8
5
9
4
0
 b
y
 g
u
e
s
t o
n
 1
4
 O
c
to
b
e
r 2
0
1
9
higher protein levels are both likely to result in function
disturbance and eventual cytotoxicity.
RRM1 has a very high afﬁnity for RNA and plays a
major role in mediating TDP-43/RNA interactions whereas
RRM2 has a lower afﬁnity for RNA and has a predomin-
antly regulatory function (Buratti and Baralle, 2001;
Lukavsky et al., 2013; Kuo et al., 2014). Functional muta-
tion or complete deletion of the RRM2 domain has a lim-
ited impact on RNA binding (Buratti and Baralle, 2001);
however, we have shown that both the K181E and K263E
mutations completely abolish the binding of TDP-43 to its
target RNA, and implying that the RRM2 does play an
important role in RNA processing. The loss of RNA bind-
ing generated abundant insoluble hyperphosphorylated
TDP-43 aggregates which are the hallmark of TDP-43 pro-
teinopathy in FTD/ALS supports the case that these muta-
tions are pathogenic. Interestingly, unlike the C-terminal
mutations clustered in the glycine-rich domain that do
not affect RNA binding, both K181E and K263E have
been identiﬁed in families with FTD with or without ALS
phenotypes. Whereas TDP-43 proteinopathy is commonly
seen in tau-negative FTD, the mutations in TDP-43 found
in FTD are still rare. Our study showed that in addition to
not binding to RNA, both K181E and K26E mutations
increase the insolubility and hyperphosphorylation of
TDP-43. It is not yet clear whether this would subsequently
trigger a distinct pathogenesis mechanism that is more
likely to affect cognitive function. Further in vivo studies
are needed to investigate the link between the loss of TDP-
43 RNA binding and the cognitive dysfunction.
The presence of TDP-43 cytoplasmic inclusions is the
hallmark of ALS and FTD but nuclear clearing is not
always present, particularly in spinal cord motor neurons
in ALS (Neumann et al., 2007; van der Zee et al., 2009;
Weihl, 2011). Many cellular and animal models of TDP-43
overexpression show neurotoxicity in the absence of nu-
clear clearance (Barmada et al., 2010; Mitchell et al.,
2015; Liu et al., 2017) thus the aggregates themselves
may be directly toxic to multiple cellular processes invol-
ving; intracellular transport, endoplasmic reticulum, mito-
chondria and proteostasis as a gain-of-function mechanism.
They could also lead to the sequestration of soluble TDP-
43 in the periphery, causing loss of normal TDP-43 protein
transport and translation as a dominant-negative effect.
TDP-43 RRM mutant proteins may be unable to process
RNA and therefore auto-regulate its own translation, they
do form aggregates and can sequester wild-type protein so
both gain- and loss-of-function effects may contribute to
neurodegeneration.
RNA chaperone
Interestingly, not only can the TDP-43 protein act as a
chaperone to protect neurons from toxic RNA (Ishiguro
et al., 2017), RNA may in turn play a role in keeping
TDP-43 soluble and preventing it from aggregating.
Target single-stranded DNA or RNA has been shown to
enhance TDP-43 protein solubility in vitro (Huang et al.,
2013; Sun et al., 2014) and the addition of an RNA-bind-
ing domain to the aggregation-prone E. coli lysol tRNA
synthetase increased its protein folding and solubility in
the presence of RNA (Choi et al., 2008). On the other
hand, TDP-43 containing the artiﬁcial mutations F147/
149L, which functionally disrupt the RRM1, forms nuclear
aggregates in cellular models and remains insoluble follow-
ing the addition of RNA (Ayala et al., 2008; Huang et al.,
2013). These results are consistent with our observation
that RNA-free TDP-43 misfolds, becomes hyperphosphory-
lated and aggregates in the nucleus and cytoplasm indicates
that the interaction with RNA plays an important role in
maintaining TDP-43 protein solubility, and could be
explored as a mean of therapeutic intervention for ALS.
In conclusion, we have identiﬁed a novel mutation adja-
cent to the RRM1 domain in a father and son with ALS
and ALS/FTD. RRM domains show marked evolutionary
conservation and variation largely absent from human
genome databases. We have shown that two TDP-43 mu-
tations, adjacent to either RRM domain, will abolish RNA
binding and promote the formation of hyperphosphory-
lated, insoluble TDP-43 aggregates that are the hallmark
of FTD and ALS, providing functional evidence that these
mutations are likely to be pathogenic. Mutant TDP-43 ag-
gregates may be directly toxic but they can also sequester
wild-type TDP-43 protein and the loss of RNA processing
function, including the autoregulation of TARDBP (TDP-
43) mRNA, would be predicted to affect a multitude of
important cellular pathways that could lead to neurodegen-
eration. As more wild-type TDP-43 becomes trapped within
aggregates, less soluble TDP-43 is available to the cell.
Eventually the RNA binding deﬁcient mutant TDP-43 can
deprive the cell of its functional RNA processing counter-
part, resulting in a dominant-negative loss-of-function.
Furthermore, our studies imply that RNA binding to
TDP-43 can inhibit its aggregation, which may open new
avenues for therapeutic intervention.
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